Literature DB >> 29262279

Nivolumab and Ipilimumab in Advanced Melanoma.

Jedd D Wolchok1, Linda Rollin2, James Larkin3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29262279     DOI： 10.1056/NEJMc1714339

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

1.  Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.

Authors:  Gerardo A Vitiello; Timothy G Bowler; Mengyuan Liu; Benjamin D Medina; Jennifer Q Zhang; Nesteene J Param; Jennifer K Loo; Rachel L Goldfeder; Frederic Chibon; Ferdinand Rossi; Shan Zeng; Ronald P DeMatteo
Journal:  J Clin Invest       Date:  2019-02-14       Impact factor: 14.808

2.  Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.

Authors:  Michael Li; Jordan S Sack; Osama E Rahma; F Stephen Hodi; Stephen D Zucker; Shilpa Grover
Journal:  Cancer       Date:  2020-09-05       Impact factor: 6.860

3.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Authors:  Matthew J Frank; Patrick M Reagan; Nancy L Bartlett; Leo I Gordon; Jonathan W Friedberg; Debra K Czerwinski; Steven R Long; Richard T Hoppe; Robert Janssen; Albert F Candia; Robert L Coffman; Ronald Levy
Journal:  Cancer Discov       Date:  2018-08-28       Impact factor: 39.397

4.  Age-Specific Incidence of Melanoma in the United States.

Authors:  Kelly G Paulson; Deepti Gupta; Teresa S Kim; Joshua R Veatch; David R Byrd; Shailender Bhatia; Katherine Wojcik; Aude G Chapuis; John A Thompson; Margaret M Madeleine; Jennifer M Gardner
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282

5.  Immunotherapy for skin cancer.

Authors:  Kelly G Paulson; Miranda C Lahman; Aude G Chapuis; Isaac Brownell
Journal:  Int Immunol       Date:  2019-07-13       Impact factor: 4.823

Review 6.  Metastatic colorectal cancer: therapeutic options for treating refractory disease.

Authors:  A Parmar; K K W Chan; Y J Ko
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

Review 7.  Kidney Complications of Immune Checkpoint Inhibitors: A Review.

Authors:  Roman Shingarev; Ilya G Glezerman
Journal:  Am J Kidney Dis       Date:  2019-07-11       Impact factor: 8.860

8.  Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Curtis R Chong; Vivian J Park; Bevin Cohen; Michael A Postow; Jedd D Wolchok; Mini Kamboj
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

9.  Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.

Authors:  Shira Peleg Hasson; Benjamin Salwen; Ayelet Sivan; Sivan Shamai; Ravit Geva; Ofer Merimsky; Ari Raphael; Haim Shmilovich; Yonatan Moshkovits; Livia Kapusta; Zach Rozenbaum; Ido Wolf; Michal Laufer-Perl
Journal:  Clin Res Cardiol       Date:  2020-04-15       Impact factor: 5.460

10.  Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.

Authors:  Chaoqi Zhang; Zhen Zhang; Feng Li; Zhibo Shen; Yamin Qiao; Lifeng Li; Shasha Liu; Mengjia Song; Xuan Zhao; Feifei Ren; Qianyi He; Bo Yang; Ruitai Fan; Yi Zhang
Journal:  Oncoimmunology       Date:  2018-08-23       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.